Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.56 |
| ▸ | SRC | P12931 | 5/20 | 0.47 |
| ▸ | BRAF | P15056 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | GCGR | P47871 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5189460 | 0.85 | USP2 (0.46) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL5789108 | 0.84 | MAPK14 (0.57) | MAPK14SRCBRAFKDRMAPK13 | |
| SCHEMBL6937114 | 0.82 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL5792669 | 0.82 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL4821019 | 0.81 | MAPK9 (0.58) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL6935696 | 0.81 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL6935697 | 0.81 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL6933880 | 0.78 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL6929508 | 0.76 | CYP3A4 (0.55) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL6934712 | 0.76 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1328277-C | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2007-07-25 | — | — | CN | disclosed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| CN-1246857-A | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | MAPK14 1169/4885SRC 4200/4885BRAF 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.